Cuprina Holdings (Cayman) LTD

Cuprina Holdings (Cayman) Limited is a Singapore-based biomedical and biotechnology company focused on developing and commercializing innovative products for chronic wound management and operating in the health and beauty sector. The company's business model revolves around leveraging biomedical research to identify and utilize natural source materials for wound care products, which are classified as medical devices, and cosmeceutical products. Revenue is generated from the sale of these products to public and private hospitals, clinics, retailers, gyms, and online platforms. The company emphasizes a commitment to quality, demonstrated by ISO 13485:2016 certification for its manufacturing facility, and a focus on sustainability by growing materials in-house or utilizing waste streams.

The company's core business is segmented into chronic wound care products and cosmeceutical products. The primary commercialized chronic wound care product line is MEDIFLY, which consists of medical-grade sterile blowfly larvae bio-dressing products used in Maggot Debridement Therapy (MDT). These products accounted for 71.2% of revenue in 2024 and 88.6% of revenue in 2025 ¹. MEDIFLY products are offered in "Free Range" and "Baggots" variants, each containing 150-250 live Lucilia cuprina larvae, and are used for non-surgical debridement, biofilm disruption, and infection reduction in chronic wounds. The company's cosmeceutical business, established in April 2023, includes three commercialized products: MEND Skin Restoration Balm, ENDURE Muscle Energy Cream, and Activ Labs Cool Relief Muscle Patch. MEND Skin Restoration Balm is a hydrating balm with collagen and plant extracts, manufactured by a Singapore-based OEM, with sales and marketing handled by Full Crimp Milk LLP under a 50/50 profit-sharing agreement ². ENDURE Muscle Energy Cream, formulated and manufactured by a Singaporean pharmaceutical company, uses transdermal delivery technology with ribose, creatine, carnitine, and caffeine. Activ Labs Cool Relief Muscle Patch, developed and manufactured by a mainland China-based OEM, provides temporary pain relief with ingredients like menthol, sodium hyaluronate, glucosamine, and chondroitin.

For the fiscal year ended December 31, 2025, Cuprina Holdings (Cayman) Limited reported total revenue of S$49,894 (US$38,789) ³. The company incurred a gross loss of S$645 (US$501) ⁴, resulting in a gross loss margin of 1.3% ⁵. Operating expenses totaled S$4,829,184 (US$3,754,322) ⁶, leading to a net loss of S$4,673,447 (US$3,633,248) ⁷. As of December 31, 2025, the company had an accumulated deficit of S$9,234,500 (US$7,179,118) ⁸. Net cash flows used in operating activities for the year ended December 31, 2025, were S$9,133,948 (US$7,100,947) ⁹. The company reported net current assets of S$4,215,760 (US$3,277,431) as of December 31, 2025 ¹⁰.

Comparing 2025 to 2024, revenue increased by 3.3% from S$48,321 to S$49,894 ¹¹. Cost of revenues decreased by 1.6% from S$51,345 to S$50,539 ¹². This led to a decrease in gross loss from S$3,024 in 2024 to S$645 in 2025 ¹³, and an improvement in gross loss margin from 6.3% to 1.3% ¹⁴. Operating expenses, however, significantly increased by 194.1% from S$1,642,235 to S$4,829,184 ¹⁵. This was primarily driven by a 228.5% increase in selling, general and administrative expenses, from S$1,400,873 to S$4,602,300 ¹⁶, largely due to increased professional fees, consultant fees, director fees, and foreign exchange losses. Research and development costs decreased by 6.0% from S$241,362 to S$226,884 ¹⁷, mainly due to the departure of an R&D employee. Other income increased by 34.8% from S$173,865 to S$234,455 ¹⁸, primarily from fees for ISO13485 certified facilities usage. Interest expense decreased by 60.4% from S$37,210 to S$14,724 ¹⁹ due to the full settlement of employee loans. The net loss widened from S$1,560,535 in 2024 to S$4,673,447 in 2025 ²⁰.

During the reported period, Cuprina Holdings (Cayman) Limited completed its IPO on April 11, 2025, raising net proceeds of approximately US$9,184,726 ²¹, with an additional US$1,800,000 from the over-allotment option on May 8, 2025, for aggregate net proceeds of US$10,849,726 ²². The company secured exclusive licensing rights for Singapore, with an option for ten additional Southeast Asian countries, to a medical waste recycling technology from Zhejiang Heliang Technology Co., Ltd. in September 2025 ²³. In April 2025, an IVF media production facility in Singapore was completed, receiving ISO 13485 certification and a dealer license from the Singapore HSA ²⁴. A joint venture agreement was entered into with Aiodine Laboratory Pte. Ltd. in November 2025 for the worldwide distribution, marketing, and commercialization of iodine-based wound care products, with Cuprina holding a 50.1% equity interest ²⁵.

Cuprina Holdings (Cayman) Limited expects to continue incurring losses for the foreseeable future and cannot assure profitability. The company's future growth relies on industry development and consumer demand for its products, requiring it to identify and respond to shifting trends, develop new products, and achieve market acceptance. Revenue growth is difficult to predict due to factors such as economic conditions, governmental regulations, timing of regulatory approvals, customer acquisition and retention, reimbursement rates, sales cycle length, sourcing delays, operating expenses, pricing, and competitor activities.

A major growth area for the company is geographic expansion into new markets, including Southeast Asia, the Middle East (specifically GCC member states), and mainland China. In Saudi Arabia, the company is registering its maggot-based chronic wound care products with the SFDA through a joint venture, having already contributed Saudi Riyal 406,700 (approximately S$147,000) in cash ²⁶. In Hong Kong, an exclusive distribution and profit-sharing agreement with Advanced Biotech and Engineering Limited, effective June 2023, facilitates the sale of MEDIFLY products. For mainland China, the company is collaborating with Nan'ao (Beijing) Hospital Management Co., Ltd. to register its maggot-based products with the NMPA, with a service fee of RMB50,000 payable to Nan'ao ²⁷. The company also plans to engage with potential distribution partners in Thailand, Malaysia, Vietnam, and Indonesia.

Another significant growth vector is the expansion of the product portfolio through development and innovation. The company is developing products utilizing leeches, bullfrog skin-derived collagen, and iodine-based formulations. The bullfrog collagen sponge dressings are expected to become commercially available to medical device distributors in the United States in the first half of 2026, contingent on FDA 510(k) clearance ²⁸. Clinical trials for bullfrog collagen sponge dressings with a local hospital partner in Singapore are targeted for 2025. Other bullfrog collagen-based wound care products, such as a hydrogel, are anticipated to have biocompatibility tests completed by the end of 2026 to 2027, with commercial availability thereafter. The joint venture with Aiodine Laboratory Pte. Ltd. aims to commercialize iodine-based wound care and topical antiseptic products, with the joint venture company paying Aiodine an annual royalty of 3% of net sales once profitable ²⁹. The company also plans to explore bullfrog collagen skincare and cosmetic products for commercial availability between 2026 and 2028.

Operationally, the company intends to expand into new business ventures: medical waste recycling technology and in-vitro fertilization (IVF) media production. In medical waste recycling, the company secured exclusive licensing rights for Singapore, with an option for ten additional Southeast Asian countries, for a technology from Zhejiang Heliang Technology Co., Ltd. in September 2025. This technology employs high-temperature steam treatment to sterilize medical waste, particularly plastic-based materials, for recycling into high-value resins. The global medical waste management market was valued at approximately USD 34.06 billion in 2023 and is projected to reach approximately USD 59.42 billion by 2030, growing at a CAGR of approximately 8% ³⁰. In IVF media production, a facility in Singapore was completed in April 2025, certified to ISO 13485, and licensed by the Singapore HSA. This facility will produce 14 SKUs of IVF media products in collaboration with Ferti-Craft Pte Ltd. Commercial sales are expected to commence before the fourth quarter of 2026, with initial sales in Singapore and planned expansion into ASEAN countries, the Middle East, and other global markets. The total ART market was valued at approximately USD 38.9 billion in 2025 and is expected to grow at a CAGR of approximately 7.6% to reach approximately USD 79.8 billion by 2035 ³¹.

The company plans to strengthen brand awareness and acquire/retain customers through participation in conferences, educational talks, website optimization, social media, targeted online advertising, and KOL engagement. They aim to recruit approximately four sales and marketing personnel and four R&D staff in the next two years ³². The company also plans to set aside a portion of its profits annually for corporate social responsibility activities, including the "Cuprina Cares" initiative launched in August 2023 to support individuals lacking access to MDT treatment due to financial difficulties.

The company faces significant risks, including a history of losses and expected future losses, with an accumulated deficit of S$9,234,500 (US$7,179,118) as of December 31, 2025 ³³. Its business and future growth are highly dependent on unpredictable consumer demand and industry development, with potential for new competitor products to render current offerings obsolete. Revenue growth is difficult to forecast, and shortfalls could lead to operating results below expectations. The company had net current liabilities as of December 31, 2023, and 2024, and net operating cash outflows for the years ended December 31, 2023, 2024, and 2025, which could constrain working capital and liquidity. The regulatory approval processes for medical devices, particularly with the FDA, are lengthy and unpredictable, with no guarantee of timely clearance or approval. Failure to manage rapid growth, especially in new products and geographic markets, could strain resources and harm operating results. Intense competition from larger, more established companies with greater resources and distribution networks poses a threat, potentially leading to pricing pressure. Security breaches could compromise sensitive data, leading to liability and reputational damage. Reliance on R&D partners and third-party manufacturers introduces risks of delays, increased costs, or termination of agreements. The lack of patent protection for MEDIFLY products, which generated 88.6% of 2025 revenue ³⁴, makes them vulnerable to competition from substantially equivalent products. The company is dependent on a few major customers, with sales to the top five accounting for 65.7% of total revenue in 2025 ³⁵, and a few major suppliers, with purchases from the top five accounting for 74.8% of cost of sales in 2025 ³⁶. Reduction or discontinuation of government grants, such as the S$16,928 (US$13,160) received in 2025 ³⁷, could adversely affect results. Expansion into new geographic markets like mainland China and Hong Kong subjects the company to evolving and uncertain regulatory environments and potential government intervention. Adverse global and local economic conditions, including heightened inflation (Singapore's core inflation rate averaged 2.7% in 2024 and 0.7% in 2025, projected to average 1.0% to 2.0% in 2026 ³⁸), recession, and financial market disruptions, could negatively impact demand, margins, and the ability to raise capital.

Management's message emphasizes a commitment to innovation in biomedical and biotechnology, focusing on chronic wound care and the health and beauty sector. They highlight their expertise in utilizing natural sources for product development and adherence to international quality standards, including ISO 13485:2016 certification. Strategic priorities include expanding into new geographic markets such as Southeast Asia, the Middle East (GCC), and mainland China, leveraging strategic partnerships to facilitate market entry and regulatory approvals. A key focus is the continuous expansion of the product portfolio through in-house R&D and collaborations, particularly for bullfrog collagen-based wound care and cosmeceutical products, and iodine-based topical antiseptics. Management also stresses the importance of new business ventures in medical waste recycling technology and IVF media production, aiming to capitalize on adjacent growth areas. They plan to strengthen brand awareness and customer loyalty through targeted marketing and patient education, and to attract and retain a talented workforce by recruiting approximately four sales and marketing personnel and four R&D staff in the next two years ³⁹. The overall tone suggests a forward-looking approach, balancing product innovation and market expansion with a commitment to quality, sustainability, and corporate social responsibility.